AIM ImmunoTech (NYSEAMERICAN:AIM) Shares Up 4.5% – Still a Buy?

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) traded up 4.5% on Friday . The stock traded as high as $1.02 and last traded at $0.9589. 1,692,022 shares changed hands during trading, a decline of 83% from the average session volume of 9,676,714 shares. The stock had previously closed at $0.9180.

Analysts Set New Price Targets

Separately, Zacks Research cut shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy”.

AIM ImmunoTech Stock Up 4.5%

The business has a 50-day moving average price of $1.03 and a two-hundred day moving average price of $1.64. The company has a market capitalization of $3.15 million, a price-to-earnings ratio of -0.05 and a beta of 1.26.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Corient Private Wealth LLC acquired a new position in shares of AIM ImmunoTech during the second quarter valued at about $87,000. DRW Securities LLC raised its holdings in shares of AIM ImmunoTech by 60.6% in the 4th quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after acquiring an additional 26,254 shares during the last quarter. Finally, Sabby Management LLC acquired a new stake in shares of AIM ImmunoTech in the 3rd quarter worth about $79,000. 12.02% of the stock is owned by institutional investors.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.